Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma

Lin,Xing-Yu; Chen,Si-Zeng

doi:10.3892/or.2017.5396

Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma

Authors:
- Xing-Yu Lin
- Si-Zeng Chen
View Affiliations

Affiliations: The First Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
Published online on: January 20, 2017 https://doi.org/10.3892/or.2017.5396
Pages: 1601-1610

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer-related cachexia involves increased protein breakdown through various proteolytic pathways, including the ubiquitin-proteasome pathway (UPP). We hypothesized that a calcium- and calpain-dependent pathway might play a crucial role during the proteolytic procedure, and that pathway interventions would ameliorate cancer cachexia in vivo. After being inoculated with CT26 adenocarcinoma cell culture subcutaneously, BALB/c mice developed cachexia in 12 days. They were then administered with different types of calpain inhibitors individually or in combination for 7 consecutive days. Eighteen healthy mice were also assessed as a control group. Changes in body weight, gastrocnemius muscle mass, tumor volume, food intake, survival time, and serum nutritional markers were monitored. Also measured were the levels of calpains, E3 ubiquitin ligases, and apoptosis-associated markers in gastrocnemius muscle. Our study showed that the intraperitoneal administration of calpain inhibitors significantly improved tumor-free body weight and gastrocnemius muscle mass in all treatment groups. Treatment with calpain inhibitors also ameliorated cachexia-associated negative effects in metabolic profiles and increased survival time in most of the tumor-bearing mice compared with the cachexia controls. Furthermore, calpain inhibitors reduced the calpain activity and the expression of MuRF-1 and atrogin-1 in all treatment groups, while increasing the level of cleaved caspase-3 and BAX and lowering the level of BCL-2 in some groups. These results justify further evaluation of calpain inhibitors both alone and in combination with other candidate agents as a potential new therapeutic strategy for treating cancer cachexia.

View Figures

View References

1	Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI
2	Baracos VE: Pitfalls in defining and quantifying cachexia. J Cachexia Sarcopenia Muscle. 2:71–73. 2011. View Article : Google Scholar : PubMed/NCBI
3	von Haehling S and Anker SD: Cachexia as major underestimated unmet medical need: Facts and numbers. Int J Cardiol. 161:121–123. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tisdale MJ: Molecular pathways leading to cancer cachexia. Physiology (Bethesda). 20:340–348. 2005. View Article : Google Scholar : PubMed/NCBI
5	Del Fabbro E: Current and future care of patients with the cancer anorexia-cachexia syndrome. Proc ASCO. e229–237. 2015.10.14694/EdBook_AM.2015.35.e229.
6	Goll DE, Neti G, Mares SW and Thompson VF: Myofibrillar protein turnover: The proteasome and the calpains. J Anim Sci. 86 Suppl:E19–E35. 2008. View Article : Google Scholar : PubMed/NCBI
7	Wing SS, Lecker SH and Jagoe RT: Proteolysis in illness-associated skeletal muscle atrophy: From pathways to networks. Crit Rev Clin Lab Sci. 48:49–70. 2011. View Article : Google Scholar : PubMed/NCBI
8	Johns N, Stephens NA and Fearon KC: Muscle wasting in cancer. Int J Biochem Cell Biol. 45:2215–2229. 2013. View Article : Google Scholar : PubMed/NCBI
9	Busquets S, Deans C, Figueras M, Moore-Carrasco R, López-Soriano FJ, Fearon KC and Argilés JM: Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr. 26:614–618. 2007. View Article : Google Scholar : PubMed/NCBI
10	Donkor IO: Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opinion on Therapeutic Patents. 21:601–636. 2011.doi: 10.1517/13543776.2011.568480. View Article : Google Scholar : PubMed/NCBI
11	Huang J and Zhu X: The molecular mechanisms of calpains on muscle atrophy. Physiol Res. 65:547–560. 2016.PubMed/NCBI
12	Zhang Z, Huang Z, Dai H, Wei L, Sun S and Gao F: Therapeutic efficacy of E-64-d, a selective calpain inhibitor, in experimental acute spinal cord injury. Biomed Res Int. 2015:1342422015.PubMed/NCBI
13	Wang C, Shi D, Song X, Chen Y, Wang L and Zhang X: Calpain inhibitor attenuates ER stress-induced apoptosis in injured spinal cord after bone mesenchymal stem cells transplantation. Neurochem Int. 97:15–25. 2016. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Donkor IO: An updated patent review of calpain inhibitors (2012–2014). Expert Opin Ther Pat. 25:17–31. 2015.PubMed/NCBI
16	Salamino F, De Tullio R, Mengotti P, Viotti PL, Melloni E and Pontremoli S: Different susceptibility of red cell membrane proteins to calpain degradation. Arch Biochem Biophys. 298:287–292. 1992. View Article : Google Scholar : PubMed/NCBI
17	Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Prado CM, Birdsell L and Falkmer U: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr. 32:65–72. 2013. View Article : Google Scholar : PubMed/NCBI
18	Amano K, Maeda I, Morita T, Okajima Y, Hama T, Aoyama M, Kizawa Y, Tsuneto S, Shima Y and Miyashita M: Eating-related distress and need for nutritional support of families of advanced cancer patients: A nationwide survey of bereaved family members. J Cachexia Sarcopenia Muscle. 7:527–534. 2016. View Article : Google Scholar : PubMed/NCBI
19	Costelli P, De Tullio R, Baccino FM and Melloni E: Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer. 84:946–950. 2001. View Article : Google Scholar : PubMed/NCBI
20	Foletta VC, White LJ, Larsen AE, Léger B and Russell AP: The role and regulation of MAFbx/atrogin-1 and MuRF1 in skeletal muscle atrophy. Pflugers Arch. 461:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
21	Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, et al: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 294:1704–1708. 2001. View Article : Google Scholar : PubMed/NCBI
22	Furlow JD, Watson ML, Waddell DS, Neff ES, Baehr LM, Ross AP and Bodine SC: Altered gene expression patterns in muscle ring finger 1 null mice during denervation- and dexamethasone-induced muscle atrophy. Physiol Genomics. 45:1168–1185. 2013. View Article : Google Scholar : PubMed/NCBI
23	van Royen M, Carbó N, Busquets S, Alvarez B, Quinn LS, López-Soriano FJ and Argilés JM: DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? Biochem Biophys Res Commun. 270:533–537. 2000. View Article : Google Scholar : PubMed/NCBI
24	Ishiko O, Sumi T, Yoshida H, Hyun Y and Ogita S: Angiogenesis in the adipose tissue of tumor-bearing rabbits treated by cyclic plasma perfusion. Int J Oncol. 19:785–790. 2001.PubMed/NCBI
25	Ray SK, Samantaray S, Smith JA, Matzelle DD, Das A and Banik NL: Inhibition of cysteine proteases in acute and chronic spinal cord injury. Neurotherapeutics. 8:180–186. 2011. View Article : Google Scholar : PubMed/NCBI
26	Ray SK, Matzelle DC, Wilford GG, Hogan EL and Banik NL: E-64-d prevents both calpain upregulation and apoptosis in the lesion and penumbra following spinal cord injury in rats. Brain Res. 867:80–89. 2000. View Article : Google Scholar : PubMed/NCBI
27	Kim KA, Lee YA and Shin MH: Calpain-dependent calpastatin cleavage regulates caspase-3 activation during apoptosis of Jurkat T cells induced by Entamoeba histolytica. Int J Parasitol. 37:1209–1219. 2007. View Article : Google Scholar : PubMed/NCBI